|Issuer:||BELLICUM PHARMACEUTICALS, INC (BLCM)|
|Original Submission Date:|
FAIR RICHARD A.
C/O BELLICUM PHARMACEUTICALS, INC.
3730 KIRBY DRIVE, SUITE 1200 HOUSTON, TX 77098
|Title of Security||Transaction Date||2a. Deemed Execution Date||Transaction Code||Shares||Acquired or Disposed||Price per share||5. Amount of Securities Beneficially Owned Following Reported Transaction||6. Ownership Form Direct or Indirect||Nature of Indirect Ownership|
|Title of Derivative Security||Conversion or Exercise Price of Derivative Security||Transaction Date||Deemed Execution Date||Transaction Code||Number of Derivative Securities Acquired (A) or Disposed of (D)||Date Exercisable||Expiration Date||Title and Amount of Securities Underlying Derivative Security||Price of Derivative Security||Number of derivative Securities Beneficially Owned Following Reported Transaction(s)||Ownership Form: Direct (D) or Indirect (I)||Nature of Indirect Beneficial Ownership|
|STOCK OPTION (RIGHT TO BUY)||2.91||2021-08-16||deemed execution date||A||265,000 (a)||2031-08-16||common stock 265,000||$2.91||265,000||direct|
|f1||50% of the shares subject to the stock option vest and become exercisable on december 15, 2021, and the remaining shares subject to the stock option vest and become exercisable in 12 equal monthly installments thereafter.|